Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates positive sentiment due to operational efficiencies, strong AUSTEDO growth, and effective cost management. Despite revenue decline, gross and operating margins improved. Management's confidence in achieving targets, especially for AUSTEDO, and strategic focus on biosimilars and innovative pipeline add to positive sentiment. Q&A insights support growth and strategic alignment with market dynamics. Positive guidance on cost savings and debt reduction further enhances the outlook. Given these factors, the stock is likely to experience a positive impact, despite some uncertainties around Medicare pricing and CMS agreements.
Key Financial Performance
Revenue $4.5 billion, up 3% year-over-year. Growth driven by innovative products and generics in the U.S., partially offset by softness in European generics and lower proceeds from product rights sales.
Adjusted EBITDA Up 6% year-over-year. Growth attributed to strong performance in innovative products and operational efficiencies.
Non-GAAP EPS $0.78, up 14% year-over-year. Increase driven by higher gross margin and operational improvements.
Free Cash Flow $515 million, down from $922 million in Q3 2024. Decrease due to timing of sales and collections, and higher legal settlement payments.
Net Debt to EBITDA Below 3x for the first time since 2016. Improvement due to consistent debt reduction and EBITDA growth.
Innovative Products Revenue Over $800 million for the quarter, up 33% year-over-year. Growth led by AUSTEDO (up 38% to $618 million), UZEDY (up 24% to $43 million), and AJOVY (up 19% to $168 million).
Global Generics Revenue Up 2% year-over-year. Growth driven by U.S. launches and biosimilars, partially offset by declines in Europe.
TAPI Revenue Down 4% year-over-year. Decline attributed to seasonal volatility.
Non-GAAP Gross Margin 55.3%, up 120 basis points year-over-year. Increase driven by strong growth in AUSTEDO and favorable portfolio mix.
Non-GAAP Operating Margin 28.9%, up 70 basis points year-over-year. Improvement due to higher gross margin and operational efficiencies.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AUSTEDO: Achieved $618 million in Q3 2025, growing 38% year-over-year. Revenue outlook for 2025 increased to $2.05 billion to $2.15 billion. Peak sales target of over $3 billion remains intact.
UZEDY: Revenue grew 24% year-over-year to $43 million. Expanded indication for bipolar I disorder. Peak sales target of $1.5 billion to $2 billion.
AJOVY: Revenue grew 19% year-over-year to $168 million. Confirmed guidance of $630 million to $640 million for 2025.
Generics Business: Revenue grew 2% year-over-year, driven by U.S. launches and biosimilars. European generics declined 5% due to tough comparisons.
Biosimilars: 10 in-line assets globally with potential to launch 6 more by 2027. Expected to add $400 million by 2027.
Cost Savings Program: On track to achieve $700 million in savings by 2027, with 2/3 realized by 2026. Approximately half of the 2025 target already achieved.
Net Debt Reduction: Net debt-to-EBITDA reduced to below 3x for the first time since 2016. Targeting 2x by 2027.
Innovative Pipeline: Late-stage assets include olanzapine LAI, DARI, duvakitug, and emrusolmin. Potential peak sales of over $11 billion.
TAPI Divestment: Renewed sale process initiated after failing to reach agreement with initial buyer. TAPI remains non-strategic to growth priorities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: Seasonal volatility in TAPI and softness in European generics markets, including tough comparisons to prior years and tender wins.
Regulatory Hurdles: AUSTEDO selected for CMS 2027 price negotiation, which could impact pricing dynamics. Additionally, potential U.S. tariffs on pharmaceuticals remain uncertain.
Supply Chain Disruptions: No explicit mention of supply chain disruptions, but seasonal volatility in TAPI could imply operational challenges.
Economic Uncertainties: Geopolitical shifts and market conditions affecting the attractiveness of TAPI for potential buyers.
Strategic Execution Risks: Challenges in divesting TAPI due to inability to reach an agreement with a buyer, impacting strategic focus and resource allocation. Additionally, reliance on achieving $700 million in cost savings by 2027 and executing late-stage innovative programs on time.
Competitive Pressures: AJOVY operates in a highly competitive market, and biosimilars face challenges in Europe, the largest biosimilar market.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Teva expects to achieve mid-single-digit revenue growth by 2027, with a 3% to 4% growth range estimated for 2025.
AUSTEDO Revenue Outlook: The company has increased its 2025 revenue outlook for AUSTEDO to $2.05 billion to $2.15 billion, with a 2027 revenue target of $2.5 billion and peak sales exceeding $3 billion.
UZEDY Revenue and Market Potential: Teva reiterates its peak sales target of $1.5 billion to $2 billion for UZEDY, supported by strong TRx growth and expanded indications. Q4 2025 revenue guidance for UZEDY is $55 million to $65 million.
AJOVY Revenue Guidance: Teva confirms its 2025 revenue guidance for AJOVY at $630 million to $640 million.
Innovative Pipeline and Future Growth: Teva anticipates over $11 billion in peak sales from its late-stage innovative pipeline, including olanzapine LAI, DARI, duvakitug, emrusolmin, and anti-IL-15 programs. Key milestones include FDA submission for olanzapine LAI in late 2025 and Phase III progress for other assets.
Generics and Biosimilars: Teva forecasts $400 million in additional biosimilar revenue by 2027, with significant contributions expected post-2027 from European launches.
Operating Margin and Cost Savings: Teva is on track to achieve a 30% operating margin by 2027, supported by $700 million in cost savings from its transformation program, with two-thirds of savings realized by 2026.
Net Debt-to-EBITDA: Teva expects to reduce its net debt-to-EBITDA ratio to 2x by 2027, with a 2025 year-end target of 2.8x.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program was made during the call.
Share Buyback Program: The presentation did not discuss any share buyback program or shareholder return plan.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the internal expectations for AUSTEDO negotiations and how does the negotiated price relate to the current Medicare net price?
A:The negotiations were in line with the company's forecast set in May 2023. The management remains confident in achieving $2.5 billion in revenue for AUSTEDO, emphasizing the underdiagnosed and undertreated condition of tardive dyskinesia. However, they did not comment on the net price for competitive reasons.
Q:What is the company's response to competitor claims about dosing creep and its impact on AUSTEDO XR's pricing and access?
A:The company focuses on treating the underserved market and executing effectively. They highlighted the benefits of AUSTEDO XR for compliance and adherence, allowing physicians flexibility in dosing. Management emphasized their thoughtful approach to managing access and value, and reiterated confidence in AUSTEDO's growth potential.
Q:Is the consensus estimate of $4.8 billion for combined R&D and SG&A in 2026 consistent with the company's cost optimization plans?
A:Yes, the company plans to achieve $700 million in savings by 2026, with most savings impacting OpEx. They expect to maintain a 27%-28% run rate for OpEx while expanding operating profit and EBITDA.
Q:Was AUSTEDO XR included in the IRA negotiations?
A:Yes, AUSTEDO XR was included in the IRA negotiations.
Q:What are the dynamics of the EU generics market and the company's strategy for growth?
A:The EU generics market is expected to grow at a 2% CAGR due to its scale. Recent growth was driven by more launches and competitors' supply issues. The company plans to focus on biosimilars in the EU, with momentum expected post-2027.
Q:Why did the company restart the TAPI sales process instead of keeping the asset?
A:The company views TAPI as strategic for sourcing APIs and ensuring value for Teva's products. Market conditions and geopolitical developments influenced the decision to revise the sales process.
Q:Can the company continue to deliver growth in revenue and EBITDA despite the Revlimid roll-off?
A:Yes, growth is driven by the innovative portfolio, cost savings, and the ability to compensate for the Revlimid roll-off through generics, complex generics, and OTC products. The company remains confident in achieving its targets.
Q:What factors contributed to the strong Q3 AUSTEDO performance, and what is expected for Q4?
A:Strong Q3 performance was due to channel stocking of AUSTEDO XR and favorable gross-to-net adjustments. Management expects consistent performance in Q4, with no significant changes anticipated.
Q:How will the FDA's new guidance on biosimilars impact the company's strategy and the market?
A:The guidance aligns with the company's strategy of having a large biosimilar portfolio through partnerships. While the removal of Phase III studies reduces costs, biosimilar development remains expensive, limiting market entry. The company expects the U.S. to follow Europe's mature biosimilar market dynamics.
Q:What are the company's expectations for CMS agreement and volume gains for AUSTEDO under IRA?
A:The CMS agreement aligns with the company's 2023 expectations. Management remains confident in achieving $2.5 billion in 2027 sales, focusing on capturing more patients and improving adherence. They will adjust modeling based on IRA dynamics observed in January.
Q:What is the status of the olanzapine LAI submission and the possibility of a Commissioner's voucher?
A:The olanzapine LAI submission is on track for this quarter. The company is reviewing the potential for a Commissioner's voucher for this or other programs.
Q:What are the enrollment timelines and indication expansion plans for duvakitug?
A:The Phase III IBD studies are designed for efficient enrollment and execution. The company is considering additional indications and combinations but is currently focused on ulcerative colitis and Crohn's disease.
Q:What are the capital allocation priorities for 2026 and the key points for achieving the 2027 free cash flow guide?
A:Priorities include strategic business development, debt reduction, and potential shareholder returns. Free cash flow growth will be driven by innovative portfolio growth, cost savings, debt reduction, and working capital optimization.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the negotiated Medicare net price for AUSTEDO, the exact percentage of CMS agreement, and the potential use of a Commissioner's voucher for olanzapine LAI.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AJOVY
AUSTEDO
Phase III
Revlimid
TAPI
Teva
UZEDY
adult patient
asset
biosimilars
buyer
cash flow
date
debt
design
designation
development milestone
disease
disorder
duvakitug
end track
generic
indication
label
launch
margin
market
peak
people
portfolio
product
progress
result
sale
saving
shift
study
transformation
TEVA Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Teva Pharmaceutical Industries Limited (TEVA) Q1 2026 Earnings Call Transcript
Unknown4-29
The earnings call shows mixed results: a slight revenue increase and improved net income, but declining operating income and free cash flow. The lack of strategic updates and forward-looking risks add uncertainty. The absence of Q&A insights and market cap data further limits sentiment clarity. Overall, a neutral market reaction is expected.
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
TEVA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
